Elena Santagostino

VP, Medicine Development Lead Haemophilia
Sobi, Stockholm, Sweden

Presentation(s):

• OC 47.4 - A Post Hoc Analysis of Individuals With Severe Hemophilia A and Inhibitors From the PUPs A-LONG Study

  Monday, July 11, 2022
  3:30 PM – 3:45 PM

• PB1153 - Interim Analysis from B-MORE, a 24-month Prospective, Multicentre, Non-interventional Study on Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM